Scarica l'app Stockscreener
82.49
0.73%
0.60
Precedente Chiudi:
$81.89
Aprire:
$83.64
Volume 24 ore:
2.48M
Relative Volume:
2.94
Capitalizzazione di mercato:
$4.51B
Reddito:
$1.34M
Utile/perdita netta:
$-173.66M
Rapporto P/E:
-19.93
EPS:
-4.1385
Flusso di cassa netto:
$-130.49M
1 W Prestazione:
+7.90%
1M Prestazione:
-1.33%
6M Prestazione:
+97.58%
1 anno Prestazione:
+372.99%
Intervallo 1D:
$79.79
$85.00
Intervallo di 1 settimana:
$77.16
$85.00
Portata 52W:
$16.64
$96.50
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
82.49 | 4.51B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Iniziato | Truist | Buy |
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares - Stock Titan
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
Dianthus Therapeutics Inc (DNTH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dianthus Therapeutics Inc (DNTH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dianthus Therapeutics Inc (DNTH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - Zacks Investment Research
Dianthus Therapeutics Inc (DNTH) Institutional Confidence - TradingKey
Dianthus Therapeutics Inc (DNTH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dianthus Therapeutics Inc (DNTH) Valuation: PE, PB & Fair Value Analysis - TradingKey
DNTH stock clocks best day in over 3 months on strong nerve disorder study results - MSN
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger - Yahoo Finance
Dianthus drops as Sanofi halts late-stage trial for CIDP therapy on efficacy concerns - MSN
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?Dianthus Therapeutics (NASDAQ:DNTH) - Benzinga
Dianthus Therapeutics posts interim CAPTIVATE responder data; 75% response in first 40 CIDP patients - TradingView
Dianthus Therapeutics (DNTH) details interim Phase 3 CIDP results, Phase 2 gMG data and $1.2B runway - Stock Titan
Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable Questions - Seeking Alpha
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Benzinga
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sahm
Guggenheim reiterates Dianthus stock rating citing potency edge By Investing.com - Investing.com Nigeria
Dianthus Therapeutics Down Over 9%, On Track for Largest Percent Decrease Since January 2025 -- Data Talk - Moomoo
Dianthus Therapeutics stock rating maintained at Buy by TD Cowen - Investing.com Canada
Dianthus Therapeutics stock falls on Sanofi CIDP trial halt By Investing.com - Investing.com South Africa
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch? - BioWorld News
Truist reiterates Dianthus Therapeutics stock rating after rival trial halt By Investing.com - Investing.com Canada
Sanofi (SNY) Halts Phase 3 Study, Impacting Dianthus Therapeutics - GuruFocus
Why is Dianthus Therapeutics stock plunging today? By Investing.com - Investing.com Canada
Stifel reiterates Dianthus Therapeutics stock Buy on rival setback By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Will Orphan Drug Status And Advancing Autoimmune Pipeline Change Dianthus Therapeutics' (DNTH) Narrative - Yahoo Finance
DNTH: Advancing potent neuromuscular and rheumatology assets with robust funding and rapid execution - TradingView
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Gross profit of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Net debt of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Enterprise value of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Net income before discontinued operations of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Return on equity % of Dianthus Therapeutics, Inc. – XETR:87E - TradingView
Dianthus Therapeutics, Inc. Balance Sheet – XETR:87E - TradingView
Dianthus Therapeutics, Inc. Statistics – XETR:87E - TradingView
BNP Paribas Financial Markets Boosts Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Eases Claseprubart Trial Screening Rules - Sahm
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline - Insider Monkey
DNTH: Multiple pivotal trials advance with key data and strong cash runway supporting growth - TradingView
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Yahoo Finance
Dianthus Therapeutics EVP Randhawa sells $2.4m in company stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics EVP Randhawa sells $2.4m in company stock - Investing.com
Dianthus Therapeutics (DNTH) EVP sells 26,530 shares after option exercises - Stock Titan
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):